Valuation: REGENXBIO Inc.

Market Cap 588M 504M 472M 431M 814M 56.07B 822M 5.57B 2.17B 28.29B 2.21B 2.16B 93.69B P/E 2026 *
-2.71x
P/E 2027 * -3.33x
Enterprise Value 579M 497M 465M 425M 802M 55.24B 810M 5.49B 2.14B 27.87B 2.18B 2.13B 92.3B EV / Sales 2026 *
3.45x
EV / Sales 2027 * 2.96x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-2.36%
1 week-19.51%
Current month-8.05%
1 month-8.43%
3 months+40.31%
6 months+4.45%
Current year-38.12%
1 week 7.77
Extreme 7.77
12.08
1 month 7.77
Extreme 7.77
12.08
Current year 5.46
Extreme 5.455
16.19
1 year 5.46
Extreme 5.455
16.19
3 years 5.04
Extreme 5.035
28.8
5 years 5.04
Extreme 5.035
46.46
10 years 5.04
Extreme 5.035
85.1
Manager TitleAgeSince
Chief Executive Officer 64 2024-06-30
Director of Finance/CFO 45 2024-09-15
Chief Tech/Sci/R&D Officer 53 2025-02-28
Director TitleAgeSince
Chairman 78 2020-06-30
Chairman 51 2024-06-30
Director/Board Member 76 2015-10-14
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Tax

Chief Technology Officer

-7,468 0.0114%
8/1/26 Tax

General Counsel

-4,699 0.0072%
7/2/26 Fiscal year

Chief Technology Officer

6,483 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
-2.81%-19.51%-0.67%-50.91% 588M
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.57%+1.78%+49.21%+90.20% 64.17B
-1.19%+22.96%+8.55%-3.03% 28.65B
-0.51%-3.56%-3.45%+467.26% 27.06B
-2.78%+5.95%+55.58%+12.15% 27.33B
-1.96%+0.65%+37.31%-17.64% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-0.57%+7.19%+538.65% 15.96B
-0.75%+6.78%+49.66%+157.94% 14.05B
Average -0.47%+2.06%+53.38%+171.86% 28.9B
Weighted average by Cap. +0.56%+3.27%+55.28%+154.45%

Financials

2026 *2027 *
Net sales 168M 144M 135M 123M 232M 16B 235M 1.59B 619M 8.07B 630M 616M 26.73B 217M 186M 174M 159M 300M 20.69B 303M 2.06B 800M 10.44B 815M 797M 34.57B
Net income -176M -151M -141M -129M -244M -16.78B -246M -1.67B -649M -8.47B -661M -647M -28.04B -200M -172M -161M -147M -277M -19.09B -280M -1.9B -738M -9.63B -752M -735M -31.89B
Net Debt -8.72M -7.47M -7M -6.39M -12.07M -831M -12.19M -82.57M -32.14M -419M -32.74M -32.02M -1.39B 53.61M 45.94M 43.05M 39.32M 74.21M 5.11B 74.94M 508M 198M 2.58B 201M 197M 8.54B
Logo REGENXBIO Inc.
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Employees
371
Date Price Change Volume
26-08-25 US$8.910 +10.61% 1,756,781
26-08-24 US$8.055 -24.86% 5,446,547
26-08-21 US$10.72 -3.07% 1,007,024
26-08-20 US$11.06 -7.99% 947,369
26-08-19 US$12.02 +8.58% 1,146,910
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
8.910USD
Average target price
23.73USD
Spread / Average Target
+166.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGNX Stock